- Home
- ODV vs GOSS Comparison
ODV vs GOSS Comparison
Compare ODV & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ODV | GOSS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 936.0M | 726.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ODV | GOSS |
|---|---|---|
| Price | $3.70 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 1.1M | ★ 2.9M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $8,089,655.00 | ★ $44,051,000.00 |
| Revenue This Year | $102.54 | N/A |
| Revenue Next Year | $106.31 | $6.41 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.16 | $0.71 |
| 52 Week High | $3.89 | $3.60 |
Technical Indicators
Market Signals| Indicator | ODV | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 63.14 | 65.88 |
| Support Level | $3.53 | $3.25 |
| Resistance Level | $3.60 | $3.54 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 97.90 | 92.62 |
Price Performance
Historical ComparisonAbout ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.